A percutaneous absorption composition

LAP576AUndetermined Publication Date: 2026-01-23MEDRX CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP576
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2015-08-29
Filing Date
2016-08-29
Publication Date
2026-01-23

AI Technical Summary

Technical Problem

Conventional techniques for enhancing the transdermal absorption of basic drugs often fail to achieve long-term stable skin permeability, particularly for certain drug types, and there is a lack of effective transdermal absorption enhancers in non-aqueous products.

Method used

A transdermal absorption composition comprising a basic drug or its salt, sorbic acid, and/or sorbic acid metal salt, combined with a base component such as organic or inorganic bases, which enhances skin permeability by forming an ionic liquid, thereby promoting the transdermal absorption of basic drugs.

Benefits of technology

The composition achieves excellent skin permeability for basic drugs, with sorbic acid and its metal salts significantly improving the transdermal absorption when used in combination with base components, as demonstrated by in vitro skin permeability tests.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure P%2F576_DRAWING_001
    Figure P%2F576_DRAWING_001
Patent Text Reader

Abstract

An object of the present invention is to provide: a percutaneous absorption composition having an improved skin permeability of a basic medicament and an agent for promoting the transdermal absorbability of a basic medicament.The object can be achieved by the use of a percutaneous absorption composition comprising a basic medicament or a salt thereof and sorbic acid and / or its metal salt.The concentration of the sorbate component is preferably from 0.5 mole to 2.5 moles per mole of the basic medicament.Preferably, the composition of the present invention may further comprise an organic basic compound and / or an inorganic basic component.
Need to check novelty before this filing date? Find Prior Art

Description

Transdermal absorption composition The present invention relates to an external preparation containing a basic drug, and more particularly to a composition containing sorbic acid as a transdermal absorption promoter. As a technique for improving the transdermal absorption of basic drugs, there is a technique of forming an equimolar salt of a basic drug and an organic acid salt to adjust the lipophilicity of the basic drug to an appropriate range (for example, Patent Document 1), and a technique of using an ionic liquid composed of a fatty acid and an organic amine compound as a transdermal absorption promoter (for example, Patent Document 2), which have achieved certain results. However, depending on the type of drug, higher skin permeability may be required, or a long-term stable preparation may not be manufacturable with conventional techniques. Sorbic acid is known as a preservative and can be used as a preservative for water-containing patches such as cataplasms (for example, Patent Document 3). However, it is not known that sorbic acid has an excellent transdermal absorption promoting effect on basic drugs, and its use as a transdermal absorption promoter and a non-aqueous transdermal absorption composition containing the same have not been known. Pamphlet of International Publication No. 2010-016219 Pamphlet of International Publication No. 2009-066457 Japanese Patent Application Laid-Open No. 2014-125483 An object of the present invention is to provide a transdermal absorption composition with improved skin permeability of a basic drug and a transdermal absorption promoter for a basic drug. As a result of intensive studies, the present inventors have found that sorbic acid has an excellent effect on promoting the transdermal absorption of basic drugs, and that the effect is further increased by combining sorbic acid and a basic component. That is, the present invention includes the following (1) to (5). (1) A transdermal absorption composition containing a basic drug or a salt thereof, sorbic acid and / or a metal salt of sorbic acid. (2) The transdermal absorption composition according to (1) above, wherein the content of the sorbic acid component is 0.5 to 2.5 moles per mole of the basic drug. (3) The transdermal absorption composition according to (1) or (2) above, further containing a basic component selected from the group consisting of an organic base compound, an inorganic base compound, and a salt of a strong base. (4)The transdermal absorption composition according to (3) above, wherein the content of the basic component is 0.4 to 3.0 moles per mole of the sorbic acid component. (5)A transdermal absorption promoter for basic drugs, comprising a sorbic acid and / or a metal salt of sorbic acid and a basic component selected from the group consisting of an organic base compound, an inorganic base compound, and a salt of a strong base. According to the present invention, there are provided a transdermal absorption composition excellent in skin permeability of basic drugs and a transdermal absorption promoter for basic drugs that exhibits an excellent transdermal absorption promoting effect. In one embodiment, there is provided a transdermal absorption composition comprising a basic drug or a salt thereof and a sorbic acid component. The sorbic acid component may include sorbic acid and / or a metal salt of sorbic acid. In one embodiment, the transdermal absorption promoter for the basic drug of the present disclosure includes a sorbic acid component. In one embodiment, the transdermal absorption promoter may further include a basic component. [Basic drug] In one embodiment, the active ingredient has a basic functional group such as an amino group. Specifically, hypnotics and sedatives such as flurazepam, lormazepam, medetomidine, dexmedetomidine; stimulants and wakefulness-promoting agents such as methamphetamine, methylphenidate; psychotropic drugs such as imipramine, diazepam, sertraline, fluvoxamine, paroxetine, citalopram, fluoxetine, alprazolam, haloperidol, clomipramine, amitriptyline, desipramine, amoxapine, maprotiline, mirtazapine, setiptiline, duloxetine, diazepam, etizolam; local anesthetics such as lidocaine, procaine, tetracaine, dibucaine; urinary organ drugs such as oxybutynin, tamsulosin, propiverine, imidafenacin, solifenacin, darifenacin, tolterodine; skeletal muscle relaxants such as tizanidine, eperisone, pridinol, suxamethonium; reproductive organ drugs such as ritodrine, meleaddrin; autonomic nerve drugs such as carpronium, neostigmine, bethanechol; anti-Parkinson's disease drugs such as pergolide, bromocriptine, trihexyphenidyl, amantadine, ropinirole, talipexole, pramipexole, rotigotine, cabergoline, selegiline, rasagiline; anti-migraine drugs such as dihydroergotamine, sumatriptan, ergotamine, flunarizine, cyproheptadine; antihistamines such as clemastine, diphenhydramine, chlorpheniramine, diphenylpyraline; bronchodilators such as tulobuterol, procaterol, salbutamol, clenbuterol, fenoterol, terbutaline, isoprenaline; cardiotonic agents such as denopamine; peripheral vasodilators such as nicametate, tolazoline; smoking cessation aids such as nicotine, varenicline; cardiovascular drugs such as atenolol, bisoprolol, metoprolol, carvedilol, carteolol, valsartan, clonidine; antiarrhythmic drugs such as propranolol, alprenolol, procainamide, mexiletine; peptic ulcer therapeutic agents such as proglumide, cetraxate, spizofurone, cimetidine; gastrointestinal motility improvers such as domperidone, cisapride; anti-allergy drugs such as ketotifen, azelastine, emedastine; antiviral drugs such as acyclovir; anti-Alzheimer's drugs such as donepezil, tacrine, arecoline, galantamine, rivastigmine;Serotonin receptor antagonist antiemetics such as ondansetron, granisetron, ramosetron, azasetron; opioid analgesics such as morphine, codeine, fentanyl, oxycodone, hydromorphone; antifungal agents such as terbinafine, butenafine, amorolfine, neticonazole, miconazole, luliconazole, itraconazole, etc. can be exemplified. Basic drugs may be used in the free state, but from the viewpoints of stability, suppression of skin irritation, etc., they can also be used as pharmaceutically acceptable acid addition salts thereof. Examples of the acid addition salts include inorganic acid salts such as hydrochloride, sulfate, hydrobromide, and organic acid salts such as fumarate, maleate, citrate, tartrate. The basic drug or its salt can be used alone or in combination of two or more. In certain embodiments, the basic drug can be selected from the group consisting of tizanidine hydrochloride, oxycodone hydrochloride, lidocaine hydrochloride, or combinations thereof. In certain embodiments, the basic drug can be at least one selected from tizanidine hydrochloride and oxycodone hydrochloride. [Sorbic acid component] Sorbic acid promotes the transdermal absorption of basic drugs. Although not proven, it is considered that sorbic acid ionically binds to basic drugs in the composition to form an ionic liquid. In certain embodiments, the ionic liquid can be tizanidine-sorbate, oxycodone-sorbate, or lidocaine-sorbate. Either free acid form of sorbic acid or metal salts of sorbic acid such as sodium sorbate, potassium sorbate, calcium sorbate can be used. Further, the free acid form of sorbic acid and the metal salt of sorbic acid can be used in combination. When sorbic acid and the metal salt of sorbic acid are used in combination, the term “sorbic acid component” is a general term for sorbic acid and the metal salt of sorbic acid. In this case, in the present specification, the “content of the sorbic acid component” means the sum of the content of sorbic acid and the content of the metal salt of sorbic acid. If sorbic acid or the metal salt of sorbic acid is used alone, the “content of the sorbic acid component” means the content of sorbic acid or the content of the metal salt of sorbic acid. The content of the sorbic acid component can be selected from the range of, for example, about 0.1 to 3.0 moles, about 0.5 to 2.5 moles, or about 0.9 to 2.1 moles per mole of the basic drug. When the content of the sorbic acid component is in the range of 0.5 to 2.5 moles per mole of the basic drug, the transdermal absorption promoting effect is remarkable. However, if it contains more than 3 moles, the skin permeability of the drug may be rather poor. [Basic component] In certain embodiments, the composition of the present disclosure may further contain a basic component. The basic component may include one or more organic base compounds, inorganic base compounds, and salts of strong bases. The inorganic base compounds and salts of strong bases may be collectively referred to as the inorganic base component. By combining and using the above-mentioned sorbic acid component and basic component, the transdermal absorption promoting effect of the basic drug is further increased. Therefore, the combination of the above-mentioned basic component and sorbic acid component can be used as an excellent transdermal absorption promoter. In certain embodiments, the organic base compound can be alkanolamines having 2 to 9 carbon atoms such as monoethanolamine, monoisopropanolamine, diethanolamine, diisopropanolamine, triethanolamine, triisopropanolamine, ethylenediamine, and tris(hydroxymethyl)aminomethane (tromethol), and basic amino acids such as arginine. In certain embodiments, the organic base compound is an organic amine having three hydroxyl groups in one molecule, such as triethanolamine, triisopropanolamine, and tris(hydroxymethyl)aminomethane. In certain embodiments, the organic base compound is triethanolamine. The organic base compound can be used alone or in combination of two or more. In certain embodiments, the inorganic base component means a compound containing an alkali metal or an alkaline earth metal. Examples of inorganic base compounds include hydroxides such as sodium hydroxide, potassium hydroxide, and calcium hydroxide. In certain embodiments, salts of strong bases include metal carboxylates such as sodium benzoate, sodium propionate, calcium propionate, sodium fumarate, sodium sorbate, and potassium sorbate; metal hydroxy acids such as sodium lactate, sodium tartrate, potassium tartrate, and sodium citrate; sodium sulfite; sodium pyrosulfite, and the like. In certain embodiments, when a metal sorbate such as potassium sorbate is employed as the “sorbic acid component”, the metal sorbate is classified not only as the “sorbic acid component” but also as the “inorganic base component”. Therefore, in the calculation of the content, the metal sorbate is added to both the “sorbic acid component” and the “inorganic base component”. In certain embodiments, when a hydrochloride salt of a basic drug is used as the active ingredient and an inorganic base component is formulated in the composition, the metal ions constituting the inorganic base compound and / or the salt of a strong base can also act as a “hydrochloride remover”. The metal ions capture the hydrochloric acid added to the basic drug to form chlorides, generating a free form of the basic drug. This is thought to improve the transdermal permeability of the drug. The content of the organic base compound and / or the inorganic base component can be in the range of about 0.4 to about 3.0 moles, about 0.5 to about 2.5 moles, about 0.5 to about 2.0 moles, or about 0.5 to about 1.6 moles per mole of the sorbic acid component. [Other Transdermal Penetration Enhancers] In certain embodiments, the composition of the present disclosure can further include one or more compounds that dissolve the drug and sorbic acid and have an action of promoting the transdermal absorption of the drug. For example, fatty acids, alcohols, ester compounds, amide compounds, and the like are useful. The composition of the present invention is a non-aqueous topical composition that substantially does not contain water. For example, the non-aqueous composition can contain less than about 3.0% or less than 1.0% water. Examples of the above fatty acids as transdermal absorption enhancers include saturated or unsaturated fatty acids having 4 to 20 carbon atoms (excluding sorbic acid) such as levulinic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, isostearic acid, and oleic acid. One or more fatty acids can be selected and used. In certain embodiments, the composition further comprises at least one unsaturated fatty acid. In certain embodiments, the unsaturated fatty acid is oleic acid. When using fatty acids in the composition, the total of sorbic acid and other fatty acids can be selected from the range of about 0.8 to about 2.5 moles, or about 0.8 to about 2.0 moles, per mole of the base component. In certain embodiments, the total weight of the sorbic acid component and the fatty acid can be about 2.0 to about 3.0% by weight, or about 2.0 to about 2.5% by weight, based on the total weight of the pressure-sensitive adhesive layer. In certain embodiments, the composition can further comprise an alcohol. Examples of the above alcohol include monohydric alcohols such as lauryl alcohol, myristyl alcohol, oleyl alcohol, isostearyl alcohol, and cetyl alcohol; dihydric alcohols such as propylene glycol, butylene glycol, dipropylene glycol, diisobutylene glycol, polyethylene glycol, and hexylene glycol; and trihydric alcohols such as glycerin and hexanetriol. In certain embodiments, the composition can comprise two or more alcohols. In certain embodiments, the composition comprises oleyl alcohol. In certain embodiments, the composition can further comprise an ester compound. Examples of the above ester compound can be diethyl sebacate, methyl laurate, diisopropyl adipate, isopropyl myristate, propylene carbonate, medium-chain fatty acid triglyceride, etc. The medium-chain fatty acid triglyceride contains a triglyceride having a fatty acid C 6-12 containing a fatty chain. In certain embodiments, the composition further comprises lauric acid. Examples of the above amide compound can include diethanolamide. In certain embodiments, the composition can be provided as a homogeneous solution by mixing a basic drug or its salt and a sorbic acid component with a base component in the solvent described above. In certain embodiments, the composition can further contain a fatty acid, an alcohol, and / or an ester compound. [Matrix-type patch formulation] The composition of the present disclosure can be made into a matrix-type patch formulation by dispersing the above solution in an adhesive layer composed of a suitable polymer. Useful polymers can include acrylic polymers, rubber polymers, silicone polymers, and vinyl ether polymers. In certain embodiments, rubber polymers such as styrene-isoprene-styrene block copolymer, styrene-butadiene-styrene block copolymer, polyisoprene, polyisobutylene, and polybutadiene can be preferably used. The content of the rubber polymer can be about 5 to about 40% by weight, about 10 to about 30% by weight, or about 5 to about 25% by weight based on the total dry weight of the adhesive layer. The content of the acrylic polymer and the silicone polymer can be about 45 to about 95% by weight, or about 50 to about 90% by weight based on the total dry weight of the adhesive layer. In certain embodiments, the adhesive layer can further contain a filler. When a filler is contained, the adhesive properties of the adhesive layer are improved and the release rate of the active ingredient is enhanced. The content of the filler can be selected, for example, from the range of about 0.5 to about 5% by weight based on the total weight of the adhesive layer. The filler can be selected from hydrous silica, fumed silica, talc, crystalline cellulose, starch, carmellose, and metal salts of carmellose. In certain embodiments, the filler can be fumed silica. A commercially available example of fumed silica can be Aerosil (registered trademark). The pressure-sensitive adhesive layer may further contain other additives such as tackifiers, softeners, antioxidants, etc. Examples of tackifiers include rosin esters, hydrogenated rosin esters, maleated rosin, alicyclic saturated hydrocarbon resins, terpene resins, polyolefin resins, etc. Examples of softeners include naphthenic process oils; vegetable oils such as camellia oil and castor oil; liquid rubbers such as liquid polybutene and liquid isoprene rubber; and liquid paraffin. Examples of antioxidants include dibutylhydroxytoluene, ascorbic acid, propyl gallate, sodium sulfite, sodium pyrosulfite, etc. When the above composition is made into a matrix-type patch preparation, the content of the basic drug can be in the range of about 0.5 to about 10% by weight, or about 1 to about 5% by weight, based on the total dry weight of the pressure-sensitive adhesive layer. Also, in certain embodiments, at least two types of alcohols are used in combination, selected from monohydric alcohols such as oleyl alcohol, dihydric alcohols such as butylene glycol and propylene glycol, and trihydric alcohols such as glycerin. In certain embodiments, the alcohol content can be about 15 to about 35% by weight, about 20 to about 30% by weight, or about 22 to about 28% by weight, based on the total dry weight of the pressure-sensitive adhesive layer. Hereinafter, the present disclosure will be described in more detail with reference to examples, but the present disclosure is not limited by these examples in any way. (Example 1) [Manufacture of a patch containing tizanidine and sorbic acid] Tizanidine hydrochloride, sorbic acid, sodium lactate, sodium benzoate, triethanolamine, diethyl sebacate, isopropyl myristate, glycerin, DiPG (dipropylene glycol), BG (butylene glycol), oleyl alcohol, propyl gallate, and liquid paraffin were mixed and heated (about 60 °C) to dissolve, obtaining a uniform solution. To this, terpene resin dissolved in toluene, styrene-isoprene-styrene block copolymer (SIS5002) dissolved in toluene, and Aerosil were added and uniformly mixed to obtain a drug-containing adhesive composition. The obtained drug-containing adhesive composition was applied onto a PET film subjected to a peeling treatment. Subsequently, it was heated and dried at 80 °C for 10 minutes to remove toluene, producing a patch containing tizanidine and sorbic acid. The composition (weight %) of each component is as shown in Table 1. (Comparative Example 1) [Production of a patch containing tizanidine and a higher fatty acid and not containing sorbic acid] In the same manner as in Example 1, a patch having the composition (weight %) shown in Table 1 was produced. (Examples 2 and Comparative Example 2) [Production of a patch containing oxycodone] In the same manner as in Example 1, a patch containing oxycodone having the composition (weight %) shown in Table 1 was produced. [In vitro skin permeability test] Using a Franz cell for a skin permeability test, the skin permeability of the drugs in the patches produced in the examples and comparative examples was evaluated. The cumulative skin permeation amounts at each sampling point are also shown in Table 1. For the patches containing tizanidine produced in Example 1 and Comparative Example 1, the test was conducted using hairless rat abdominal skin, and for the patches containing oxycodone produced in Example 2 and Comparative Example 2, the test was conducted using pig skin. The patch of Example 1-1 containing sorbic acid showed high skin permeability compared to the patches of Comparative Examples 1-1 to 1-4 that did not contain sorbic acid but instead contained higher fatty acids. Even in the patches of Example 2 and Comparative Example 2 containing oxycodone instead of tizanidine, the patches of the present invention containing sorbic acid (Example 2-1 and Example 2-2), similar to the patches containing tizanidine, showed high skin permeability compared to the patches that did not contain sorbic acid. (Example 3) [Examination of Optimal Content of Sorbic Acid and Basic Component] Patches were produced with the compositions (by weight) shown in Table 2. An in vitro skin permeability test was conducted on the obtained patches using rat skin. The results are also shown in Table 2. All of the patches of Examples 3-1 to 3-9 containing sorbic acid showed excellent skin permeability. However, the patch of Example 3-1 had slightly inferior skin permeability because the content of sorbic acid relative to the basic component was low. The patches of Examples 3-7 to 3-9 with a high content of sorbic acid relative to tizanidine also had slightly inferior skin permeability. (Example 4) [Examination of Optimal Basic Component] Patches containing sorbic acid and various basic components were produced with the compositions (by weight) shown in Table 3. An in vitro skin permeability test was conducted on the obtained patches using rat skin. The results are also shown in Table 3. All of the patches of Examples 4-1 to 4-8 contained sorbic acid and showed excellent skin permeability because the content ratio of sorbic acid to the drug and the content ratio of the basic component to sorbic acid were appropriate. (Example 5) Patches were produced with the compositions (by weight) shown in Table 4. An in vitro skin permeability test was conducted on the obtained patches using pig skin. The results are also shown in Table 4. When potassium sorbate was used as the sorbic acid component, it also showed high skin permeability similar to the case when sorbic acid was used. (Example 6) A patch was produced with the composition (by weight) shown in Table 5. An in vitro skin permeability test using porcine skin was conducted on the obtained patch. The results are also shown in Table 5. The patches of Examples 6-1 to 6-4 containing sorbic acid all showed excellent skin permeability. The transdermal absorption composition of the present invention can be utilized, for example, as a patch preparation containing a basic drug such as tizanidine or oxycodone.

Claims

1. A transdermal absorption composition containing a basic drug or a salt thereof, and sorbic acid and / or a metal salt of sorbic acid.

2. The transdermal absorption composition according to claim 1, wherein the content of the sorbic acid component is 0.5 to 2.5 moles per mole of the basic drug.

3. The transdermal absorption composition according to claim 1 or 2, further comprising a base component selected from the group consisting of an organic base compound, an inorganic base compound, and a salt of a strong base.

4. The transdermal absorption composition according to claim 3, wherein the content of the base component is 0.4 to 3.0 moles per mole of the sorbic acid component.

5. A transdermal absorption promoter for a basic drug, comprising sorbic acid and / or a metal salt of sorbic acid, and a base component selected from the group consisting of an organic base compound, an inorganic base compound, and a salt of a strong base.